Bibliografía
1.Rudic, JS, G Poropat, MN Krstic, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.
1. Rudic JS, Poropat G, Krstic MN, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.
2. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology2006;130:715-20.
3. Corpechot C, Abenavoli L, Rabahi N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2008;48:871-7.
4. Kuiper EM, Hansen BE, de Vries RA, et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology2009;136:1281-7.
5. Zhang, LN, Shi TY, Shi XH, et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology2013;58:264-72.
6. Ohira H, Sato Y, Ueno T, et al.Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol2002;97:2147-9.
7. Dohmen K, Mizuta T, Nakamuta M, et al.Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol2004;10:894-8.
8. Walker LJ, Newton J, Jones DE, et al.Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2009;49:337-8.
9. Liberopoulos EN, Florentin M, Elisaf MS, et al.Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J2010;4:120-6.
10. Levy C, Peter JA, Nelson DR, et al.Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment PharmacolTher2011;33:235-42.
11. Han XF,. Wang QX, Liu Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis2012;13:219-24.
12. Lindor KD, Gershwin ME, Poupon R, et al.Primary biliary cirrhosis. Hepatology2009;50: 291-308.
13. Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-49.
14. Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int2014;34:197-203.
15. Suk KT, Baik SK, Yoon JH, et al.Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol2012;18:1-21.
16. Pannu N, Nadim MK.An overview of drug-induced acute kidney injury.Crit Care Med2008;36(4 Suppl): S216-23.
17. Schetz M, Dasta J, Goldstein S, et al.Drug-induced acute kidney injury.CurrOpinCrit Care2005;11:555-65.
18. Mehta RL, Kellum JA, Shah SV, et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.CritCare 2007;11:R31.
19. Levey AS, Stevens LA, Schmid CH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med2009;150: 604-12.
20. Levey AS, Coresh J, Greene T, et al.Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.ClinChem2007;53:766-72.
21. Aithal GP, Watkins PB, Andrade RJ,et al.Case Definition and Phenotype Standardization in Drug-Induced liver injury. Clin Pharmacol Ther. 2011;89:806-15.
22. Hegade VS, Khanna A, Walker LJ, et al.Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Dig Dis Sci2016; 61:3037-44.
23. Cheung AC, Lapointe-Shaw L, Kowgier M, et al.Combinedursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment PharmacolTher2016;43:283-93.
24. Yang F, Yang Y, Wang Q, et al., The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment PharmacolTher2017;45: 733-43.
25. Attridge RL, Linn WD, Ryan L, et al. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J ClinLipidol2012;6:19-26.
26. Ansquer JC, Dalton RN, Causse E, et al.Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis2008;51:904-13.
27. Zhao YY, Weir MA, Manno M, et al.New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med2012;156:560-9.
28. Attridge RL, Frei CR, Ryan L, et al.Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm2013;70:1219-25.
29. Bonds DE, Craven TE, Buse J, et al.Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.Diabetologia2012;55:1641-50.
30. Mychaleckyj JC, Craven T, Nayak U, et al.Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35:1008-14.